Topics:
Melanoma/Skin Cancer • Medical Oncology
What is your approach to the initial treatment of metastatic melanoma patients with NRAS mutations?
How do you treat these patients if they progress after immune checkpoint inhibitors?
Answer from: Medical Oncologist at Academic Institution
The incidence of NRAS mutations in the metastatic setting has been reported in up to 15-20% of patients. There are currently no FDA approved agents specifically for NRAS mutated patients who progress after immunotherapy. Some studies have shown these patients may have bett...
Sign in or Register to read more